RT Journal Article
SR Electronic
T1 mRNA aggregates harness danger response for potent cancer immunotherapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.12.23287108
DO 10.1101/2023.03.12.23287108
A1 Mendez-Gomez, Hector R.
A1 DeVries, Anna
A1 Castillo, Paul
A1 Stover, Brian D.
A1 Qdaisat, Sadeem
A1 Von Roemeling, Christina
A1 Ogando-Rivas, Elizabeth
A1 Weidert, Frances
A1 McGuiness, James
A1 Zhang, Dingpeng
A1 Chung, Michael C.
A1 Li, Derek
A1 Zhang, Chong
A1 Marconi, Christiano
A1 Campaneria, Yodarlynis
A1 Chardon-Robles, Jonathan
A1 Grippin, Adam
A1 Karachi, Aida
A1 Thomas, Nagheme
A1 Huang, Jianping
A1 Milner, Rowan
A1 Sahay, Bikash
A1 Sawyer, W. Gregory
A1 Ligon, John A.
A1 Silver, Natalie
A1 Simon, Eugenio
A1 Cleaver, Brian
A1 Wynne, Kristine
A1 Hodik, Marcia
A1 Molinaro, Anette
A1 Guan, Juan
A1 Kellish, Patrick
A1 Doty, Andria
A1 Lee, Ji-Hyun
A1 Carrera-Justiz, Sheila
A1 Rahman, Maryam
A1 Gatica, Sebastian
A1 Mueller, Sabine
A1 Prados, Michael
A1 Ghiaseddin, Ashley
A1 Mitchell, Duane A.
A1 Sayour, Elias J.
YR 2023
UL http://medrxiv.org/content/early/2023/03/17/2023.03.12.23287108.abstract
AB Messenger RNA (mRNA) has emerged as a remarkable tool for COVID-19 prevention but its use for induction of therapeutic cancer immunotherapy remains limited by poor antigenicity and a regulatory tumor microenvironment (TME). Herein, we develop a facile approach for substantially enhancing immunogenicity of tumor-derived mRNA in lipid-particle (LP) delivery systems. By using mRNA as a molecular bridge with ultrapure liposomes and foregoing helper lipids, we promote the formation of ‘onion-like’ multi-lamellar RNA-LP aggregates (LPA). Intravenous administration of RNA-LPAs mimics infectious emboli and elicits massive DC/T cell mobilization into lymphoid tissues provoking cancer immunogenicity and mediating rejection of both early and late-stage murine tumor models. Unlike current mRNA vaccine designs that rely on payload packaging into nanoparticle cores for toll-like receptor engagement, RNA-LPAs stimulate intracellular pathogen recognition receptors (RIG-I) and reprogram the TME thus enabling therapeutic T cell activity. RNA-LPAs were safe in acute/chronic murine GLP toxicology studies and immunologically active in client-owned canines with terminal gliomas. In an early phase first-in-human trial for patients with glioblastoma, we show that RNA-LPAs encoding for tumor-associated antigens elicit rapid induction of pro-inflammatory cytokines, mobilization/activation of monocytes and lymphocytes, and expansion of antigen-specific T cell immunity. These data support the use of RNA-LPAs as novel tools to elicit and sustain immune responses against poorly immunogenic tumors.Competing Interest StatementD.A.M. holds ownership interest in iOncologi, Inc. The manuscript discusses patented technologies from H.M.G, P.C., S.Q., J.M., A.G., J.H., W.G.S., M.R., D.A.M., and E.J.S. Patented technologies are under option to license by iOncologi, Inc. The other authors declare no conflicts.Clinical TrialNCT04573140Funding StatementThis work was supported by federal awards W81XWH-17-1-0510; K08CA199224; R37CA251978; R01CA266857; R01FD007268 (FDA Office of Orphan Products Development); Florida Department of Health 20B11 (Bankhead Coley) and 20L07 (Live Like Bella) awards; and foundation grants from CureSearch (Catapult Award); The Rally Foundation; Hyundai Hope on Wheels (Hope-Scholar Award); St. Baldrick's; Chance for Life; Team Jack; Stop Children's Cancer; Danny's Dream; and The National Pediatric Cancer Foundation. Funding is also supported in part by the University of Florida Interdisciplinary Center for Biotechnology Research with funding provided by NIH Grant (1S10OD020026). J.G. acknowledges support R35GM146877 from NIGMS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of Florida gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors